|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effect of negative air ions on fog and smoke 显示文摘 | Sawant V S Meena G S Jadhav D B | 2012 | Aerosol and Air Quality Research2012，，12： | 1 |
| 2 | Causality of injury and outcome inpatients admitted in a major trauma center in North India显示文摘 | Rastogi D Meena S Sharma V | 2014 | Int J Crit Illn Inj Sci2014，4，4： | 1 |
| 3 | Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results显示文摘AIM To assess the real-world effectiveness and cost of simeprevir(SMV), and/or sofosbuvir(SOF)-based therapy for chronic hepatitis C virus(HCV) infection.METHODS The real-world performance of patients treated with SMV/SOF ± ribavirin(RBV), SOF/RBV, and SOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(SVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with SVR12 were identified using multivariable logistic regression.RESULTS SVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on SMV/SOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on SOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on SOF/PEG/RBV. Mean costs-per-SVR 12 were $174442(standard deviation: ± $18588) for SMV/SOF ± RBV; $223003(± $77946) for SOF/RBV; and $126496(± $31052) for SOF/PEG/RBV. Among patients on SMV/SOF ± RBV, SVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of SVR12 among patients on SOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of SVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on SOF/PEG/RBV. CONCLUSION SVR 12 rates for SMV and/or SOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs. | Kian Bichoupan Neeta Tandon James F Crismale Joshua Hartman David Del Bello Neal Patel Sweta Chekuri Alyson Harty Michel Ng Keith M Sigel Meena B Bansal Priya Grewal Charissa Y Chang Jennifer Leong Gene Y Im Lawrence U Liu Joseph A Odin Nancy Bach Scott L Friedman Thomas D Schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch | 2017 | World Journal of Virology2017，6，4： | 1 |
| 4 | Biological Management of Sclerotium Wilt of Jasmine显示文摘 | RAMAMOORTHY V ALICE D MEENA B | 2000 | Indian Journal of Plant Protection2000，28，1： | 1 |
| 5 | Effect of negative air ions on fog and smoke显示文摘 | Sawant V S Meena G S Jadhav D B | 2012 | Aerosol and Air Quality Research2012，12，5： | 1 |
| 6 | Record of tailed jay butterfly Graphiumagamemlum (Linnaeus, 1758) (Lepidoptera,Papilionidae) from central aravalli foothills,ajmer,rajasthan,india显示文摘 | SHARMA V KUMAWAT R MEENA D | 2012 | Journal on New Bio- logical Report2012，1，1： | 1 |
| 7 | Teak Plantation-A Potential Source of Income Generation显示文摘 | Dotaniya M L Meena V D Manju Lata | 2013 | Popular Kheti2013，1，3： | 1 |
| 8 | A Case for silicon fertilization to improve crop yields in tropical soils显示文摘 | Meena V D Dotaniya M L Coumar V | 2014 | Proceed Nation Acade Sci India Section B:Biolog Sci2014，84，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员